J&J's Centocor To Develop Super Charged Antibodies Using Xencor's Technology
This article was originally published in The Pink Sheet Daily
Executive Summary
Under the licensing deal, Centocor has rights to use Xencor's XmAb and Xtend technologies to develop and commercialize and antibodies.
You may also be interested in...
Deals Of The Week: Pfizer/Protalix, AstraZeneca/Targacept, Chiesi/Phenomix
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.
Deals Of The Week: Pfizer/Protalix, AstraZeneca/Targacept, Chiesi/Phenomix
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.
In Obtaining Strong Price From BMS, Medarex Also Ameliorates Significant Pipeline Pressure
Bristol's acquisition offer of $16 per share is certainly generous, but Medarex has a lengthy and promising pipeline to offer and one which would have needed deep pockets down the road.